Blueprint Medicines Showcases AYVAKIT's Long-Term Benefits for Patients with Indolent Systemic Mastocytosis Blueprint Medicines recently highlighted impressive long-term data showing AYVAKIT's effectiveness and safety in treating indolent systemic mastocytosis, as presented at the 2026 AAAAI Annual Meeting.

Blueprint Medicines Showcases AYVAKIT's Long-Term Benefits for Patients with Indolent Systemic Mastocytosis #United_States #Philadelphia #AYVAKIT #Systemic_Mastocytosis #Blueprint_Medicines

Blueprint Medicines Showcases AYVAKIT's Long-Term Benefits for Systemic Mastocytosis at ASH Annual Meeting Blueprint Medicines has presented updated data on AYVAKIT at the ASH Annual Meeting, demonstrating its long-term efficacy for systemic mastocytosis.

Blueprint Medicines Showcases AYVAKIT's Long-Term Benefits for Systemic Mastocytosis at ASH Annual Meeting #USA #Orlando #AYVAKIT #Blueprint_Medicines #Mastocytosis

Blueprint Medicines Presents Long-Term AYVAKIT®/AYVAKYT® Efficacy at Major Congresses Blueprint Medicines showcased significant findings on AYVAKIT®/AYVAKYT® treatment at two major congresses, emphasizing its sustained efficacy and safety profile for systemic mastocytosis.

Blueprint Medicines Presents Long-Term AYVAKIT®/AYVAKYT® Efficacy at Major Congresses #USA #Cambridge #AYVAKIT #Blueprint_Medicines #avapritinib

Sanofi Enhances Immunology Portfolio with Blueprint Medicines Acquisition Sanofi's recent acquisition of Blueprint Medicines strengthens its position in rare immunology, adding innovative therapies to its portfolio. Learn more about this strategic move.

Sanofi Enhances Immunology Portfolio with Blueprint Medicines Acquisition #Paris #France #AYVAKIT #Blueprint_Medicines #Sanofi

Blueprint Medicines Achieves Strong Q1 2025 Performance with AYVAKIT Revenue Surge Blueprint Medicines delivers impressive Q1 2025 results, with a significant increase in AYVAKIT revenues and an optimistic financial outlook.

Blueprint Medicines Achieves Strong Q1 2025 Performance with AYVAKIT Revenue Surge #United_States #Cambridge #AYVAKIT #Blueprint_Medicines #avapritinib

Blueprint Medicines Showcases Advanced Mast Cell Treatment Options at 2025 AAAAI/WAO Joint Congress Blueprint Medicines reveals promising data on AYVAKIT® and BLU-808 at the 2025 AAAAI/WAO Joint Congress, highlighting advancements in mast cell disease treatments.

Blueprint Medicines Showcases Advanced Mast Cell Treatment Options at 2025 AAAAI/WAO Joint Congress #USA #San_Diego #AYVAKIT #Blueprint_Medicines #BLU-808

Blueprint Medicines Reports Strong Financial Performance and Growth Plans for AYVAKIT® in 2025 Blueprint Medicines announced robust fourth-quarter results for AYVAKIT, projecting significant revenue growth in 2025, showcasing a promising path ahead.

Blueprint Medicines Reports Strong Financial Performance and Growth Plans for AYVAKIT® in 2025 #USA #Cambridge #AYVAKIT #Blueprint_Medicines #BLU-808

Blueprint Medicines Unveils Growth Strategy and Revenue Outlook for 2025 Blueprint Medicines has set an ambitious strategy for growth heading into 2025, aiming for significant revenue boosts driven by its key offerings, particularly AYVAKIT.

Blueprint Medicines Unveils Growth Strategy and Revenue Outlook for 2025 #United_States #Cambridge #AYVAKIT #Blueprint_Medicines #BLU-808

Blueprint Medicines Showcases Advances in Systemic Mastocytosis Treatment at 2024 ASH Annual Meeting Blueprint Medicines highlighted its significant advancements in systemic mastocytosis treatment, particularly AYVAKIT, at the 2024 ASH Annual Meeting showcasing long-term clinical benefits.

Blueprint Medicines Showcases Advances in Systemic Mastocytosis Treatment at 2024 ASH Annual Meeting #United_States #San_Diego #AYVAKIT #Systemic_Mastocytosis #Blueprint_Medicines